NovaBridge Biosciences (NBP) EBITDA (2019 - 2025)

NovaBridge Biosciences (NBP) has 5 years of EBITDA data on file, last reported at -$86.2 million in Q4 2025.

• EBITDA for Q4 2025 came in at -$86.2 million, down 127.73% year-over-year; the trailing twelve-month figure through Dec 2025 was -$80.2 million (down 4326.57% YoY), and the FY2025 annual result was -$80.2 million, down 180.18% from the prior year.
• EBITDA eased to -$86.2 million in Q4 2025 per NBP's latest filing, from $11.0 million in the prior quarter.
• Over five years, EBITDA peaked at $25.1 million in Q2 2024 and troughed at -$86.2 million in Q4 2025.
• A 3-year average of -$12.8 million and a median of -$3.1 million in 2025 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 1823.23% in 2025 and fell as far as 127.73% in 2025.
• A 3-year view of EBITDA shows it stood at -$39.5 million in 2023, then increased by 4.13% to -$37.8 million in 2024, then slumped by 127.73% to -$86.2 million in 2025.
• Business Quant data shows NBP's EBITDA at -$86.2 million in Q4 2025, $11.0 million in Q3 2025, and -$1.9 million in Q2 2025.